Page
1, 2
Clinical Results with the
Peskin Protocol
Physicians utilizing the Peskin Protocol report significant improvements in patient
outcomes across a broad spectrum of conditions.
"The Hidden Story of Cancer has provided a great breakthrough in the treatment
of our cancer patients. The addition of 5-725 mg Peskin Protocol EFA capsules
t.i.d. along with our protocol has brought a dramatic difference; unbelievable
and rapid improvement:
- Patient 1: 80-lb female with
stage III lung cancer was in full remission in 90
days.
- Patient 2: Two inoperable brain tumors (1 cm), unable to speak
or navigate - had 40% reduction of both tumors in 60 days. Patient
is
able to walk and
speak
almost normally.
- Patient 3: 8cm x 3 cm liver tumor told by his physician
he had 30 days survival time. In 60 days of therapy, patient gained
30 pounds, 80% of
tumor had calcified.
Patient felt strong enough to return to work.
- Patient 4: P.A.D. unable
to walk more than 30 feet; with seven days of Peskin Protocol EFAs,
she could walk four blocks.
"In ten days time, one can see a physical improvement in patient
condition. We believe Peskin Protocol EFAs are the ‘missing link'
in cancer therapy. The cost of treating our patients has dropped from
$20,000 (US) per month to $1,500 per month by eliminating the use of
eight IVs daily. We saw no side effects. Within two weeks, patients
typically see a great physical and mental improvement."
Bernardo C.
Majalca, ND
Stage 4 Cancer Researcher and Consultant
San Diego, California "I have been using the Peskin Protocol EFAs (YES brand) for
the last five months. I have had excellent reports from patients. Previously,
I was recommending fish oil to almost all my patients. Some improved,
specifically those with joint pains and heart disease. However, I did
not see any improvement in my diabetic/HTN patients or those w/dermatologic
problems. In fact, the latter group actually got worse. These patients
had eczematous type rashes and psoriasis.
"After reviewing Brian's data regarding the concentration ratios of parent
Omega 6 to parent Omega 3 in various tissues, it all made sense – five
out of six of my worst dermatologic cases showed good to very good improvement
in as little as three months with Peskin Protocol.
"Just taking Omega 3 alone (flax or fish oil) without regard to the appropriate
balance can adversely affect diabetic patients. This was proven in two of my
patients. These patients kept meticulous records regarding their blood sugars
and the effect of diet on their glucose levels. Without changing their diets,
they noticed significant elevations in the glucose levels after Omega 3 fatty
acids for three to four months; one pt. had an increase of 40 points.
"After starting the YES balanced blend of parent Omega 6 and 3, not only did
their BS normalize to more normal values, but they felt better overall and
both commented that their energy level improved.
"Use of the Peskin Protocol in clinical practice has made a strong believer
out of me, and I will continue to recommend this product to ALL my patients
and refer them to Peskin's research for more information."
Angelo A. Della
Pietra, MD, DO
Family and Integrative Medicine, Poughkeepsie, New York
"Having implemented EFA supplementation for over 25 years, clinical
results were mediocre until I began using the Peskin Protocol. Dr.
Rudin's work with flax oil was important but lacked clinical
effectiveness; likewise with Horrobin regarding GLA from Borage, Black
Currant, and Evening Primrose oils. Unlike the studies suggested, fish
oil, too, was disappointing. Finally, I read The
Hidden Story of Cancer which introduces the Peskin Protocol. Once implemented, I experienced
clinical success.
"Although Brian's book deals extensively, but not exclusively, with cancer
prevention, utilizing his protocol I have seen positive results (dermatological,
cardiovascular, pediatric, and neurological) in over 100 of my patients."
Abram
Ber, MD
Preventive Medicine/Homeopathic Physician "As a practicing cardiologist, I have a strong interest in
both the treatment and prevention of cardiovascular disease. As Brian
details, the paramount discovery by Otto Warburg regarding oxygenation
must also be considered the most important physiologic discovery in
the cardiovascular disease arena. Given the understanding of Warburg's
principles, as amplified and clarified by Brian, I have been enabled
and am encouraged to incorporate this information in the form of "Nutritional
Life Style" recommendations for my patients. Brian has advanced
the basic science principles of Warburg into a practical, cost-effective
formula – the Peskin Protocol – for patient care utilizing
an increased scientific understanding of Omega 6 and Omega 3 essential
fatty acid ratios.
"For those patients in my practice, and others I am aware of (100s), willing
to embrace these basic principles, I have seen clinical improvement and success
without adverse effects. Brian Peskin, in my opinion, has diligently and carefully
"teased out" from the available, published scientific data base the links necessary
to explain, understand, and help combat the most prominent cardiovascular disease
state faced by patients."
David N. Sim, MD
Cardiologist, Boise, Idaho
About the Author
Brian Scott Peskin earned
his Bachelor of Science degree in Electrical Engineering from Massachusetts
Institute
of Technology (MIT) in 1979.
He founded the field of Life-Systems Engineering Science in 1995. Brian
was appointed an adjunct professor at Texas Southern University in
the Department of Pharmacy and Health Sciences for 1998-1999. Today,
he is an independent researcher, exclusively devoting the last five
years to the cause and solution of cancer.
This article is based on
information in The Hidden Story of Cancer,
written by Brian Peskin with clinical researcher Amid Habib, MD,
FAAP, FACE (reviewed in this
issue of Townsend Letter). The
book is available from Pinnacle Press, P.O. Box 56507, Houston, Texas
77256, USA, or by phoning 1-800-456-9941
(toll-free in North America) or +1-713-979-0065 internationally.
For more information, visit www.BrianPeskin.com.
Notes
1. Weinberg RA. One Renegade Cell: How Cancer
Begins. New York: Basic
Books; 1998:64.
2. Harris H, Miller OJ, Klein G, Worst P, Tachibana T. Suppression
of malignancy by cell fusion. Nature. 1969;223:363-368.
3. Berger E. Cancer: looking beyond mutations. Houston Chronicle. June
27, 2005:1.
4. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Intake of fruits
and vegetables and risk of breast cancer: a pooled analysis of cohort
studies. JAMA. 2001;285:769-776, 799-801.
5. Epstein S, Bertell R, Seaman B. Dangers and unreliability of mammography:
Breast examination is a safe, effective, and practical alternative.
Int Journal Health Services. 2001;31:605-615.
6. Fuchs CS, Giovannucci EL, Colditz GA, et al. Dietary fiber and the
risk of colorectal cancer and adenoma in women. N
Engl J Med. 1999;340:169-176.
7. Levin B. Dietary intake and occurrence of colorectal adenoma. Lancet. 2000;356:1286-1287, 1300-1306.
8. Calder PC. Omega-3 polyunsaturated fatty acids, inflammation and
immunity. The International Society for the Study of Fatty Acids and
Lipids (ISSFAL) 4th Congress, June 4-9, 2000, Tsukuba, Japan.
9. MacLean CH, Newberry SJ, Mojica WA, et al. Effects of omega-3 fatty
acids on cancer risk. JAMA. 2006;295:403-415.
10. Hooper L, Thompson RL, Harrison RA, et al. Risks and benefits of
omega-3 fats for mortality, cardiovascular disease, and cancer: systematic
review. BMJ. 2006;332:752-760.
11. Shephard TH, Pyne GE, Kirschvink JF, McLean M. Soybean goiter:
Report of three cases. New Engl J Med. 1960;262:1099-1103.
12. Bowman DE. Differentiation of soy bean antitryptic factors. Proceed
Soc Exp Biol Med. 1946;63:547.
13. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern
and risk of invasive breast cancer: the Women's Health Initiative
Randomized Controlled Dietary Modification Trial. JAMA. 2006;295:629-642.
14. Warburg O. The prime cause and prevention of cancer (Lindau Lecture).
Revised. Würzburg, Germany: Konrad Triltsch, 1969. (English Edition,
Dean Burk, National Cancer Institute, Bethesda, Maryland, USA.) Available
at: http://www.hopeforcancer.com/OxyPlus.htm. Accessed August 11, 2006.
15. Goldblatt H, Cameron G. Induced malignancy in cells from rat myocardium
subjected to intermittent anaerobiosis during long propagation in vitro.
J Exp Med. 1953;97:525-552.
16. Malmgren, RA, Flanigan CC. Localization of the vegetative form
of Clostridium tetani in mouse tumors following intravenous spore administration.
Cancer Res. 1955;15:473-478.
17. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely
affects the prognosis of carcinoma of the head and neck. Int.
J. Radiat. Oncol. Biol. Phys. 1997;38:285-290.
18. Hockel M, Knoop C, Schlenger K, et al. Intratumoral P02 predicts
survival in advanced cancer of the uterine cervix. Radiother
Oncol. 1993;26:45-50.
19. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts
for the likelihood of distant metastases in human soft tissue sarcoma.
Cancer Res. 1996;56:941-943.
20. Campbell IM, Crozier DN, Caton RB. Abnormal fatty acid composition
and impaired oxygen supply in cystic fibrosis patients. Pediatrics. 1976;57:480-486.
21. Murray RK, Granner DK, Mayes PA, Rodwell VW. Harper's
Illustrated Biochemistry. 26th edition. New York: McGraw-Hill; 2003.
22. Meisenberg G, Simmons WH. Principles of
Biomedical Chemistry. 1st
edition. New York: Mosby; 1998.
23. Sinclair HM. Prevention of coronary heart disease: the role of
essential fatty acids. Postgrad Med J. 1980;56:579-584.
24. Sinclair HM. Essential fatty acids in perspective. Hum
Nutrit. 1984;38C:245-260.
25. Spector AA. Plasma free fatty acid and lipoproteins as sources
of polyunsaturated fatty acid for the brain. J
Mol Neurosci. 2001;16:159-65;
discussion 215-221.
26. Andersson A, Sjödin A, Hedman A, Olsson R, Vessby B. Fatty
acid profile of skeletal muscle phospholipids in trained and untrained
young men. Am J Physiol Endocrinol Metab. 2000;279:E744-E751.
27. Chapkin RS, Ziboh VA, Marcelo CL, Voorhees JJ. Metabolism of essential
fatty acids by human epidermal enzyme preparations: evidence of chain
elongation. J Lipid Res. 1986;27:945-954.
28. Garaulet M, Pérez-Llamas F, Pérez-Ayala M, et al.
Site-specific differences in the fatty acid composition of abdominal
adipose tissue in an obese population from a Mediterranean area: relation
with dietary fatty acids, plasma lipid profile, serum insulin, and
central obesity. Am J Clin Nutr. 2001;74:585-591.
29. Burns CP, Luttenegger DG, Dudley DT, Buettner GR, Spector AA. Effect
of modification of plasma membrane fatty acid composition on fluidity
and methotrexate transport in L1210 murine leukemia cells. Cancer
Research.
1979;39:1726-1732.
30. Sinclair AJ, Attar-Bashi NM, Li D. What is the role of alpha-linolenic
acid for mammals? Lipids. 2002;37:1113-1123.
31. Pawlosky RJ, Hibbeln JR, Lin Y, et al. Effects of beef- and fish-based
diets on the kinetics of n-3 fatty acid metabolism in human subjects.
Am J Clin Nutr. 2003;77:565-572.
32. Lands WEM, Morris A, Libelt B. Quantitative effects of dietary
polyunsaturated fats on the composi-tion of fatty acids in rat tissues.
Lipids. 1990;25:505-551.
Page 1, 2
|